New England Research & Management Inc. Has $514,000 Holdings in AstraZeneca PLC $AZN

New England Research & Management Inc. reduced its holdings in shares of AstraZeneca PLC (NASDAQ:AZN) by 58.0% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 6,697 shares of the company’s stock after selling 9,253 shares during the quarter. New England Research & Management Inc.’s holdings in AstraZeneca were worth $514,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in AZN. Fayez Sarofim & Co raised its position in shares of AstraZeneca by 173.4% in the second quarter. Fayez Sarofim & Co now owns 3,745,902 shares of the company’s stock valued at $261,764,000 after purchasing an additional 2,376,032 shares during the period. Valeo Financial Advisors LLC boosted its holdings in shares of AstraZeneca by 14,797.3% during the 2nd quarter. Valeo Financial Advisors LLC now owns 2,322,638 shares of the company’s stock worth $162,306,000 after buying an additional 2,307,047 shares during the period. Acadian Asset Management LLC boosted its holdings in shares of AstraZeneca by 2,389.9% during the 2nd quarter. Acadian Asset Management LLC now owns 2,043,850 shares of the company’s stock worth $142,798,000 after buying an additional 1,961,764 shares during the period. Jennison Associates LLC grew its stake in AstraZeneca by 15.2% in the 2nd quarter. Jennison Associates LLC now owns 12,167,365 shares of the company’s stock valued at $850,255,000 after buying an additional 1,605,133 shares during the last quarter. Finally, Raymond James Financial Inc. raised its holdings in AstraZeneca by 64.8% in the 2nd quarter. Raymond James Financial Inc. now owns 3,783,251 shares of the company’s stock valued at $264,373,000 after acquiring an additional 1,487,662 shares during the period. 20.35% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on AZN. Morgan Stanley reaffirmed an “overweight” rating and issued a $103.00 target price on shares of AstraZeneca in a research report on Wednesday, December 3rd. Cowen reissued a “buy” rating on shares of AstraZeneca in a research report on Tuesday, December 9th. Guggenheim reaffirmed a “buy” rating on shares of AstraZeneca in a research report on Wednesday, December 3rd. HSBC restated a “buy” rating and set a $108.00 target price on shares of AstraZeneca in a research report on Wednesday, December 10th. Finally, Jefferies Financial Group initiated coverage on AstraZeneca in a research note on Monday, October 27th. They issued a “buy” rating for the company. Eight research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, AstraZeneca has a consensus rating of “Moderate Buy” and a consensus price target of $95.75.

AstraZeneca Stock Up 1.9%

Shares of AZN opened at $91.56 on Tuesday. The firm has a 50 day simple moving average of $87.15 and a two-hundred day simple moving average of $79.37. The company has a debt-to-equity ratio of 0.54, a current ratio of 0.88 and a quick ratio of 0.69. AstraZeneca PLC has a one year low of $61.24 and a one year high of $94.01. The company has a market cap of $283.97 billion, a P/E ratio of 30.42, a P/E/G ratio of 1.66 and a beta of 0.32.

AstraZeneca (NASDAQ:AZN) last announced its quarterly earnings data on Thursday, November 6th. The company reported $1.19 earnings per share for the quarter, topping the consensus estimate of $1.14 by $0.05. The business had revenue of $15.19 billion during the quarter, compared to the consensus estimate of $14.75 billion. AstraZeneca had a return on equity of 32.89% and a net margin of 16.17%.AstraZeneca’s revenue for the quarter was up 12.0% on a year-over-year basis. During the same period in the prior year, the company earned $2.08 EPS. Research analysts forecast that AstraZeneca PLC will post 4.51 EPS for the current fiscal year.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.